Clinical Trials Arena on MSN1d
Amgen’s gMG therapy cuts disease symptoms at one-year mark
Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...
Renal & Urology News2d
Anti-C1q Antibodies in IgG4-Related Disease Associated With Renal and Skin Manifestations
Anti-C1q antibodies are highly prevalent among patients with IgG4-RD, particularly those with renal and skin manifestations.
Clinical Trials Arena on MSN13d
Immune-Onc doses first subject in trial of IO-108 for HCC
Immune-Onc Therapeutics has dosed the first subject in the Phase Ib/II trial of IO-108 plus Roche’s atezolizumab and ...
Healio9d
Response to peanut patch treatment increases through 60 months
Percentages of children with peanut allergy who responded to treatment with the VP250 VIASKIN Peanut patch from DBV ...
BioWorld2d
INA-03 demonstrates efficacy in preclinical models of triple-negative breast cancer
Inatherys SAS recently presented preclinical data for INA-03, an anti-transferrin receptor (TfR1/CD71) antibody-drug conjugate (ADC), being developed for the treatment of triple-negative breast cancer ...
Nature2mon
Isotype selection in antibody engineering
The properties of the different IgG isotypes should be considered in developing therapeutic antibodies. To address this problem, antibody engineers introduced a serine-to-proline substitution that ...